SEPN — Septerna, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1984086 ·
Last close
$30.65
Market Cap
$1.38B
52W High
$30.78
52W Low
$22.78
ADV30
355,940
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 26,523,000 | — | -13,300,000 | -8,637,000 | 569,688,000 | 71,605,000 | 191,230,000 |
| Dec 2025 | 24,118,000 | — | -16,023,000 | -10,738,000 | 596,187,000 | 120,722,000 | 214,261,000 |
| Sep 2025 | 21,495,000 | — | -9,886,000 | 8,173,000 | 606,653,000 | 319,989,000 | 217,922,000 |
| Jun 2025 | 119,000 | — | -28,978,000 | -24,838,000 | 415,231,000 | 189,311,000 | 37,674,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$110,189,000
Investing CF
$-229,352,000
Financing CF
$1,689,000
CapEx
$-518,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.11
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-167,253,000
Inventory
—
Receivables
$13,740,000
ST Investments
$270,367,000
EBIT TTM
$-80,797,000
Pretax Income TTM
$-48,867,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$72,255,000
EBITDA
$-66,559,000
Free Cash Flow
$24,014,124
Enterprise Value
$954,031,104
Total Cash
$347,400,992
Total Debt
$23,090,000
Shares Out
45,075,533
Trailing EPS
$-0.80
Book Value
$8.52
ROE
-9.3%
ROA
-8.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,951,000 | -80,797,000 | -48,879,000 | 596,187,000 | 214,261,000 | — | 110,189,000 |
| Dec 2024 | 1,075,000 | -80,823,000 | -71,798,000 | 456,554,000 | 36,507,000 | — | -67,470,000 |
| Dec 2023 | 151,000 | -45,550,000 | 4,180,000 | 130,867,000 | 169,241,000 | — | -38,723,000 |
| Dec 2022 | 0 | -27,967,000 | -27,676,000 | 36,119,000 | 80,320,000 | — | -23,303,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | $1.34B | $18.23 | — |
| KALV | KalVista Pharmaceuticals, Inc. | $1.43B | $26.81 | — |
| URGN | UroGen Pharma Ltd. | $1.44B | $29.46 | — |
| BCAX | Bicara Therapeutics Inc. | $1.44B | $21.98 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.30B | $27.94 | — |
News headlines (Yahoo Finance, 1h cache)
Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts
2026-05-17 14:47 · Yahoo
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported And Analysts Are Boosting Their Estimates
2026-05-15 14:08 · Yahoo
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 21:25 · Yahoo
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
2026-05-11 20:01 · Yahoo
Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates
2026-05-11 11:45 · Yahoo
How Analyst Upgrade and Conference Spotlight Will Impact Septerna (SEPN) Investors
2026-05-08 13:19 · Yahoo
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 23:05 · Yahoo
Septerna to Present at Bank of America Securities Health Care Conference
2026-05-05 12:00 · Yahoo
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
2026-05-04 12:15 · Yahoo
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
2026-04-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.